One of the primary causes of death for women is still cervical cancer globally. Despite advancements in conventional therapies, limitations such as drug resistance, toxicity, and recurrence highlight the urgent need for safer and more effective alternatives. The overexpression of Ubiquitin C-terminal hydrolase L3 (UCHL3) protein significantly linked to many cases in cervical cancer, so it is a viable tactic to enhance cervical cancer treatment. This study was designed to explore phytochemical as natural inhibitor of UCHL3 in cervical cancer. In this study, in-silico techniques were used to identify role of phytochemicals as inhibitors of UCHL3. Through molecular docking, binding potential of 95 naturally occurring phytochemicals were evaluated against UCHL3. Ligands (phytochemicals) were selected and screened on ADMET criteria which are useful for identifying compounds as therapeutic agents. Among docked compounds, top one compound Wistin emerged as strong binder because of its lowest binding energy (-7.7) and more stability within active site of UCHL3. Farrerol, natural ligand of UCHL3 was used as reference compound and its docking result with UCHL3 gave the binding energy of -7.0, indicating stability and efficacy of wistin. This validation showed that obtained phytochemical (wistin) is more stable compound than naturally bind ligand (farrerol) and can be used to inhibit the overexpression of UCHL3 and supports the exploration of phytochemicals as novel, less toxic alternatives for cervical cancer management.